In response to new lab testing, L’Oreal SA has issued a voluntary recall of its Effaclar Duo in the U.S.
In recent testing, independent U.S. Lab Valisure found high levels of benzene in acne treatments containing benzoyl peroxide (BPO) made by several companies.
Benzene is a known carcinogen that can form at high levels in products containing BPO, a common ingredient for killing acne-causing bacteria.
Last year, Valisure filed a petition with the US FDA calling for the regulator to recall products, investigate, and revise industry guidance. So far, the FDA has not responded.
Previously, testing found high benzene levels in aerosols including spray-on sunscreen and dry shampoos.
In this recent round of testing, high levels of benzene were found in the air around incubated BPO products, showing that benzene can leak out of some product packages and pose a potential inhalation risk.
In a statement to Bloomberg, L’Oreal SA commented,
“In close coordination with the FDA, we have proactively decided to remove the limited remaining units of the current formula of Effaclar Duo from retailers.”
The Effaclar Duo is a La Roche-Posay acne treatment that contains BPO. L’Oréal stated that this recall will assist in a seamless transition to its new and improved Effaclar Duo formula, which has been in development since 2024.
In recent testing, independent U.S. Lab Valisure found high levels of benzene in acne treatments containing benzoyl peroxide (BPO) made by several companies.
Benzene is a known carcinogen that can form at high levels in products containing BPO, a common ingredient for killing acne-causing bacteria.
Last year, Valisure filed a petition with the US FDA calling for the regulator to recall products, investigate, and revise industry guidance. So far, the FDA has not responded.
Previously, testing found high benzene levels in aerosols including spray-on sunscreen and dry shampoos.
In this recent round of testing, high levels of benzene were found in the air around incubated BPO products, showing that benzene can leak out of some product packages and pose a potential inhalation risk.
In a statement to Bloomberg, L’Oreal SA commented,
“In close coordination with the FDA, we have proactively decided to remove the limited remaining units of the current formula of Effaclar Duo from retailers.”
The Effaclar Duo is a La Roche-Posay acne treatment that contains BPO. L’Oréal stated that this recall will assist in a seamless transition to its new and improved Effaclar Duo formula, which has been in development since 2024.
Read Next
Babyganics Voluntarily Recalls ‘Totally Tropical’ SPF 50+ Mineral Sunscreen
First Aid Beauty Issues Voluntary Recall of Its Ultra Repair Cream
Charlotte Tilbury Issues Voluntary Recall of a Setting Spray
Drunk Elephant Voluntarily Recalls Three Products
